Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 49 articles:
HTML format
Text format



Single Articles


    August 2017
  1. BRAUN R, Holler E
    Acute Ocular Graft-versus-Host Disease.
    N Engl J Med. 2017;377:676.
    PubMed     Text format    


    June 2017
  2. STONE RM, Mandrekar SJ, Sanford BL, Laumann K, et al
    Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    N Engl J Med. 2017 Jun 23. doi: 10.1056/NEJMoa1614359.
    PubMed     Text format     Abstract available



  3. Blinatumomab for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:e49.
    PubMed     Text format    



  4. Blinatumomab for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:e49.
    PubMed     Text format    


  5. SPIVAK JL
    Myeloproliferative Neoplasms.
    N Engl J Med. 2017;376:2168-2181.
    PubMed     Text format    


    May 2017
  6. GORDON SW, Krystal GW
    Auer Rods.
    N Engl J Med. 2017;376:2065.
    PubMed     Text format    


    April 2017
  7. GREMBECKA J, Cierpicki T
    Stabilizing the Mixed Lineage Leukemia Protein.
    N Engl J Med. 2017;376:1688-1689.
    PubMed     Text format    


    March 2017
  8. KHAN U, Hadid T
    Plasmacytomas and Plasma-Cell Leukemia.
    N Engl J Med. 2017;376:e19.
    PubMed     Text format    


  9. HOCHHAUS A, Larson RA, Guilhot F, Radich JP, et al
    Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
    N Engl J Med. 2017;376:917-927.
    PubMed     Text format     Abstract available


  10. LONGO DL
    Imatinib Changed Everything.
    N Engl J Med. 2017;376:982-983.
    PubMed     Text format    


  11. KANTARJIAN H, Stein A, Gokbuget N, Fielding AK, et al
    Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
    N Engl J Med. 2017;376:836-847.
    PubMed     Text format     Abstract available


    February 2017
  12. MONTALBAN-BRAVO G, Takahashi K, Garcia-Manero G
    Decitabine in TP53-Mutated AML.
    N Engl J Med. 2017;376:796-7.
    PubMed     Text format    


  13. WELCH JS, Petti AA, Ley TJ
    Decitabine in TP53-Mutated AML.
    N Engl J Med. 2017;376:797-8.
    PubMed     Text format    


    November 2016
  14. WELCH JS, Petti AA, Miller CA, Fronick CC, et al
    TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    N Engl J Med. 2016;375:2023-2036.
    PubMed     Text format     Abstract available


  15. MORI J, Tsuda K, Tanimoto T
    Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016;375:2100.
    PubMed     Text format    



  16. Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016;375:2100-2101.
    PubMed     Text format    


  17. ESTEY E
    Acute Myeloid Leukemia - Many Diseases, Many Treatments.
    N Engl J Med. 2016;375:2094-2095.
    PubMed     Text format    


    September 2016
  18. MAURY S, Chevret S, Thomas X, Heim D, et al
    Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016;375:1044-53.
    PubMed     Text format     Abstract available


  19. MILANO F, Gooley T, Wood B, Woolfrey A, et al
    Cord-Blood Transplantation in Patients with Minimal Residual Disease.
    N Engl J Med. 2016;375:944-53.
    PubMed     Text format     Abstract available


  20. LEMONNIER F, Inoue S, Mak TW
    Genomic Classification in Acute Myeloid Leukemia.
    N Engl J Med. 2016;375:900-1.
    PubMed     Text format    



  21. Genomic Classification in Acute Myeloid Leukemia.
    N Engl J Med. 2016;375:900-1.
    PubMed     Text format    


    August 2016
  22. OTHUS M, Estey E, Gale RP
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


  23. MORIN-ZORMAN S, Renneville A, Ades L
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


  24. BACCARANI M
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


  25. HILLS RK, Ivey A, Grimwade D
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;375:e9.
    PubMed     Text format    


    July 2016
  26. DAVIDS MS, Kim HT, Bachireddy P, Costello C, et al
    Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
    N Engl J Med. 2016;375:143-53.
    PubMed     Text format     Abstract available


  27. TIBERGHIEN P, Follea G, Muller JY
    Platelet Transfusions in Acute Leukemia.
    N Engl J Med. 2016;375:96-7.
    PubMed     Text format    


    June 2016
  28. GOTLIB J, Kluin-Nelemans HC, George TI, Akin C, et al
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
    N Engl J Med. 2016;374:2530-41.
    PubMed     Text format     Abstract available


  29. LORENZO ME, Carter JB, Barnes JA, Nazarian RM, et al
    CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 19-2016. A 65-Year-Old Man with End-Stage Renal Disease and a Pruritic Rash.
    N Engl J Med. 2016;374:2478-88.
    PubMed     Text format    


  30. KANTARJIAN HM, DeAngelo DJ, Stelljes M, Martinelli G, et al
    Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


  31. VINY AD, Levine RL
    Roads Diverge--A Robert Frost View of Leukemia Development.
    N Engl J Med. 2016;374:2282-4.
    PubMed     Text format    


  32. PAPAEMMANUIL E, Gerstung M, Bullinger L, Gaidzik VI, et al
    Genomic Classification and Prognosis in Acute Myeloid Leukemia.
    N Engl J Med. 2016;374:2209-21.
    PubMed     Text format     Abstract available


  33. WALTER HS, Salles GA, Dyer MJ
    New Agents to Treat Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:2185-6.
    PubMed     Text format    


  34. ZAMAN F, Savendahl L
    New Agents to Treat Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:2185.
    PubMed     Text format    


  35. ROBERTS AW, Davids MS, Seymour JF
    New Agents to Treat Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:2186-7.
    PubMed     Text format    


    May 2016
  36. SHAPIRO MF
    Considering the Common Good--The View from Seven Miles Up.
    N Engl J Med. 2016;374:2006-7.
    PubMed     Text format    


    April 2016
  37. RUCHLEMER R, Ami RB, Lachish T
    Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available


  38. RIGOLIN GM, Cavazzini F, Cuneo A
    Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available


  39. SHARMAN JP, Mato AR, Keating MJ
    Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available



  40. Ibrutinib for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2016;374:1592-5.
    PubMed     Text format     Abstract available


    March 2016
  41. LO-COCO F, Di Donato L, Schlenk RF
    Targeted Therapy Alone for Acute Promyelocytic Leukemia.
    N Engl J Med. 2016;374:1197-8.
    PubMed     Text format    



  42. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.
    N Engl J Med. 2016;374:998.
    PubMed     Text format     Abstract available


  43. ARMSTRONG GT, Chen Y, Yasui Y, Leisenring W, et al
    Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.
    N Engl J Med. 2016;374:833-42.
    PubMed     Text format     Abstract available


    February 2016
  44. IVEY A, Hills RK, Simpson MA, Jovanovic JV, et al
    Assessment of Minimal Residual Disease in Standard-Risk AML.
    N Engl J Med. 2016;374:422-33.
    PubMed     Text format     Abstract available


  45. BURKE MJ
    Minimal Residual Disease in NPM1-Mutated AML.
    N Engl J Med. 2016;374:481-2.
    PubMed     Text format    


    January 2016
  46. WILSON WH
    Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.
    N Engl J Med. 2016;374:386-8.
    PubMed     Text format    


    December 2015
  47. BYRD JC, Harrington B, O'Brien S, Jones JA, et al
    Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


  48. ROBERTS AW, Davids MS, Pagel JM, Kahl BS, et al
    Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


  49. BURGER JA, Tedeschi A, Barr PM, Robak T, et al
    Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    N Engl J Med. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: